Cerity Partners’s Axsome Therapeutics AXSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.38M Buy
5,627
+242
+4% +$52.5K ﹤0.01% 1794
2026
Q1
$910K Sell
5,385
-4
-0.1% -$691 ﹤0.01% 1913
2025
Q4
$984K Sell
5,389
-15
-0.3% -$2.09K ﹤0.01% 1735
2025
Q3
$656K Sell
5,404
-248
-4% -$27.9K ﹤0.01% 1820
2025
Q2
$590K Sell
5,652
-55
-1% -$5.82K ﹤0.01% 1777
2025
Q1
$666K Buy
5,707
+766
+16% +$87.3K ﹤0.01% 1617
2024
Q4
$419K Buy
4,941
+1,198
+32% +$110K ﹤0.01% 1865
2024
Q3
$336K Buy
+3,743
New +$327K ﹤0.01% 1984

Other funds holding AXSM

Cerity Partners's AXSM Position: Q2 2026 in Review

Cerity Partners increased its Axsome Therapeutics (AXSM) stake by 4.5% in Q2 2026, buying an estimated $52.5K and bringing the position to 5,627 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #1794.

Cerity Partners first reported a position in AXSM in Q3 2024 and has held it in 8 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Cerity Partners held 5,627 shares of Axsome Therapeutics worth $1.38M as of Q2 2026.
  • Cerity Partners bought 242 Axsome Therapeutics shares in Q2 2026, an estimated $52.5K.
  • Axsome Therapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #1794 holding.
  • Cerity Partners first reported a position in Axsome Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.